Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Olverembatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 04 Jun 2025 Planned primary completion date changed from 31 Jul 2025 to 7 Mar 2027.
- 18 Feb 2025 New trial record